Table 2.
Descriptive analysis for procurement of negotiated drugs.
| Variables | Molecule | before September 2017 | after September 2017 | Diff (%) |
|---|---|---|---|---|
| Monthly average procurement expenditure (1000 US dollars) |
Rituximab | 573 | 912 | 59.4 |
| Trastuzumab | 717 | 1611 | 124.8 | |
| RHE | 274 | 305 | 11.9 | |
| Pegaspargase | 55 | 84 | 54.1 | |
| Monthly average procurement volume | Rituximab | 1036 | 2699 | 160.5 |
| Trastuzumab | 5922 | 36,721 | 520.1 | |
| RHE | 2752 | 4075 | 48.1 | |
| Pegaspargase | 1210 | 1878 | 55.2 | |
| Availability (%) |
Rituximab | 10 | 10 | 0.0 |
| Trastuzumab | 7 | 14 | 100.0 | |
| RHE | 9 | 10 | 11.1 | |
| Pegaspargase | 5 | 4 | −20.0 |